Key Points

Vaccination coverage rates, typically measured at age 2 (for children born in 2015), stabilized in 2017 in the departments of the Pays de la Loire region, remaining at the national average. For pneumococcal and hepatitis B vaccines, coverage remained slightly below the target of at least 95%. For MMR, coverage fell short, averaging only 80%.

In 2018, the mandatory vaccination against 11 diseases began to show its first positive effects on the use of the hexavalent vaccine (including hepatitis B) among infants subject to this requirement and, indirectly, on the administration of the first dose of the MMR vaccine during 2018 (among one-year-old infants eligible for MMR vaccination).

Regarding meningococcal C, vaccination coverage in the target population (ages 1–24) is insufficient, particularly among adolescents and young adults (<33%). These coverage levels do not provide the herd immunity necessary to stop the circulation of the bacterium and indirectly protect infants under one year of age, who are particularly vulnerable.
→ These shortcomings justified the addition of a transitional dose of vaccine at 5 months of age to the April 2017 vaccination schedule. In 2018, 78%
of infants received this dose, which may have contributed to the observed decrease in the disease’s incidence.

Vaccination coverage for “human papillomavirus” remains largely insufficient, with only three out of ten teenage girls protected by age 16. This does not allow for the expectation of a significant long-term impact on precancerous or cancerous lesions of the cervix in adults.

Just under half of the at-risk target population received the flu vaccine last winter.